A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5050 participants.
Also called NCT02861534
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,050 participants
- Registry
-
NCT02861534 -
2016-000671-25
-
- Other papers using this trial's data
- Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
- Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial
- Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
- Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
- Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial
- Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial
- Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
- Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
- Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02861534. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-06-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
- Acronym
- VICTORIA
- Condition
- Heart Failure
- Condition
- Chronic Heart Failure With Reduced Ejection Fraction
- Intervention (Drug)
- Vericiguat
- Intervention (Drug)
- Placebo for vericiguat
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Bayer
- Collaborator
- Canadian VIGOUR Centre
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct02861534- Content hash
6e52b794b563815c8b3f51c2c6f78f14e129cdf520ae48fd13d812c85a90c787